

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**COMP/M.6266 - J&J / SYNTHES**

**SECTION 1.2**

**Description of the concentration**

On 27 September 2011, Johnson & Johnson (“J&J”), submitted a notification of a proposed concentration pursuant to Article 4(2) of the EC Merger Regulation, by which J&J proposes to acquire within the meaning of Article 3(1)(b) of the EC Merger Regulation control of the whole of the undertaking Synthes, Inc. (“Synthes”), by way of purchase of shares.

Both J&J and Synthes are U.S.-headquartered companies.

The activities of the undertakings concerned by the notified transaction are as follows:

- J&J is the ultimate parent company of a global group of companies whose activities are divided into three business segments: (i) Consumer, (ii) Pharmaceutical, and (iii) Medical Devices and Diagnostics (“MD&D”). The notified concentration falls within the MD&D segment. J&J is active in the orthopaedic medical devices sector through its DePuy family of companies.
- Synthes is the ultimate parent of a global group of companies active in the supply of medical devices used for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.

